Savara (NASDAQ:SVRA) Trading Up 6.6% – Time to Buy?

Savara Inc. (NASDAQ:SVRA) shares were up 6.6% during mid-day trading on Wednesday . The stock traded as high as $5.26 and last traded at $5.2550. Approximately 278,516 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 1,514,531 shares. The stock had previously closed at $4.93.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SVRA shares. William Blair set a $10.00 price target on Savara in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.14.

Savara Trading Up 3.5%

The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The business has a 50-day moving average of $5.29 and a 200-day moving average of $5.60. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -9.41 and a beta of 0.26.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts anticipate that Savara Inc. will post -0.57 EPS for the current year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently modified their holdings of SVRA. Polar Capital Holdings Plc acquired a new stake in shares of Savara in the fourth quarter valued at about $50,086,000. RTW Investments LP acquired a new stake in shares of Savara in the fourth quarter valued at about $35,893,000. VR Adviser LLC increased its position in shares of Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after acquiring an additional 5,626,624 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Savara in the fourth quarter valued at about $27,496,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Savara in the fourth quarter valued at about $14,539,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.